Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nilotinib - Novartis Pharmaceuticals Corporation

Drug Profile

Nilotinib - Novartis Pharmaceuticals Corporation

Alternative Names: AMN-107; Nilotinib-nanoparticle-formulation-Xspray-Pharma; RightSize-nilotinib; Tasigna

Latest Information Update: 30 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals Corporation
  • Developer Centre Hospitalier Univeristaire De Lille; Dana-Farber Cancer Institute; Hospital for Special Surgery; Novartis Pharmaceuticals Corporation; Seoul St. Mary's Hospital; University Health Network of Toronto; University of California, San Diego
  • Class Antineoplastics; Benzamides; Fluorinated hydrocarbons; Imidazoles; Ketones; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Gastrointestinal stromal tumours; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia
  • Phase II Acral lentiginous melanoma; Gastrointestinal stromal tumours; Glioblastoma; Graft-versus-host disease; Malignant melanoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Acute myeloid leukaemia
  • No development reported Colorectal cancer; Head and neck cancer; Hypereosinophilic syndrome; Systemic scleroderma
  • Discontinued Eosinophilia

Most Recent Events

  • 09 Dec 2023 Efficacy and adverse event data from a phase II DANTE trial in Chronic myeloid leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
  • 02 Oct 2023 Novartis completes a phase II trial for Gastrointestinal stromal tumours in Japan (PO) (NCT01863745)
  • 28 Sep 2023 No recent reports of development identified for clinical-Phase-Unknown development in Hypereosinophilic-syndrome in Unknown (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top